Technology evaluation: EMD-273063, EMD Lexigen.
EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen Research Center Corp (a subsidiary of Merck KGaA) and its sister company, EMD Pharmaceuticals Inc, for the potential treatment of neuroblastoma and melanoma, for which it is in preclinical and phase I clinical trials, respectively.
Niculescu-Duvaz
Ion
I
CRC Laboratory, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. ion@icr.ac.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy; D010330:Patents as Topic; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; C493743:lorukafusp alfa